{
    "nct_id": "NCT03099109",
    "official_title": "A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors",
    "inclusion_criteria": "* For Ph1a monotherapy and combination cohorts, histologic or cytologic confirmation of advanced solid tumor.\n* For Phase 1a and 1b, prior PD-1 or PD-L1 therapy or other immunotherapy is allowed, if the following criteria are met:\n\n  * Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.\n  * Must have completely recovered or recovered to baseline prior to screening from any prior AEs occurring while receiving prior immunotherapy.\n* Must have provided tumor tissue sample, as follows:\n\n  * For participants entering Ph1a: have submitted, if available, an archival tumor tissue sample.\n  * For participants entering Ph1b: have submitted, a sample from a newly obtained core or excisional biopsy of a tumor lesion or a recent biopsy defined by 6 months of study enrollment (Ph1b).\n* Must have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) scale.\n* Must have adequate organ function.\n* Have an estimated life expectancy of 12 weeks, in judgement of the investigator.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids (participants receiving anticonvulsants are eligible).\n* Have received a live vaccine within 30 days before the first dose of study treatment.\n* If female, is pregnant, breastfeeding, or planning to become pregnant.\n* Have a history or current evidence of any condition, therapy, or laboratory abnormality that might interfere with the participant's participation.\n* Have moderate or severe cardiovascular disease.\n* Have a serious concomitant systemic disorder that would compromise the participant's ability to adhere to the protocol, including active or chronic infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV), active hepatitis C virus (HCV), active autoimmune disorders, or prior documented severe autoimmune or inflammatory disorders requiring immunosuppressive treatment.\n* Use of escalating or chronic supraphysiologic doses of corticosteroids or immunosuppressive agents (such as, cyclosporine). [Use of topical, ophthalmic, inhaled, and intranasal corticosteroids permitted].\n* Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection.\n* Evidence of interstitial lung disease or noninfectious pneumonitis.",
    "miscellaneous_criteria": ""
}